$1.56+0.08 (+5.41%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Universe Pharmaceuticals (UPC) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 45% below its peak, net margin −20.6%.
The four lines that matter · FY21–FY25
Revenue ($B)▼22.4%
17.9
FY21→FY25CAGR +339.2%/yr
Net income ($B)▲57.9%
−3.7
one-off year: see footnoteCAGR —
Free cash flow ($B)▲45.2%
−5.3
FY21→FY25CAGR —
Diluted EPS▲98.7%
−8.06
no value for 1 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+0.0%
455.9mn → 455.9mn diluted shares since FY25. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$266.8M
+28.1% YoY in FY25 · 1.5% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-21¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 52.8% → 35.3%. Net margin -20.6% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | FY25 † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 17,858.7 | 17,858.7 | 23,024.5 | 32,308.7 | 40.1 | 48.0 | ▼22.4% | +339.2% |
Cost of revenue | 11,557.6 | 11,557.6 | 16,952.6 | 21,993.6 | 18.3 | 22.7 | ▼31.8% | +375.2% |
Gross profit | 6,301.2 | 6,301.2 | 6,071.9 | 10,315.1 | 21.9 | 25.3 | ▲3.8% | +297.2% |
Research & development | 671.8 | 671.8 | 3,031.1 | 4,858.5 | 7.6 | 5.5 | ▼77.8% | +233.0% |
Selling, general & admin | 8,545.3 | 8,545.3 | 11,060.6 | 9,422.7 | 21.3 | 6.3 | ▼22.7% | +507.6% |
Total operating expenses | 9,698.2 | 9,698.2 | 14,091.7 | 14,281.2 | 28.9 | 11.7 | ▼31.2% | +436.2% |
Operating incomefeeds ROC rank | −2,915.9 | −2,915.9 | −8,019.8 | −3,966.1 | −7.0 | 13.6 | ▲63.6% | — |
Other income, net | −756.1 | −756.1 | −100.8 | −361.3 | −0.1 | 0.1 | — | — |
Pretax income | −3,672.1 | −3,672.1 | −8,120.6 | −4,327.4 | −7.1 | 13.7 | ▲54.8% | — |
Income tax | 0.0 | 0.0 | 606.7 | 2,253.6 | 0.8 | 2.4 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −3,672.1 | −3,672.1 | −8,727.3 | −6,581.0 | −7.9 | 11.4 | ▲57.9% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −8.06 | −8.06 | −626.96 | −1089.21 | −1309.11 | — | ▲98.7% | — |
Diluted shares (mn) | 455.87 | 455.87 | 13.92 | 6.04 | 0.01 | 21.75 | ▲3174.9% | +114.0% |
| Margins | ||||||||
Gross margin18th pct in Healthcare | 35.3% | 35.3% | 26.4% | 31.9% | 54.5% | 52.8% | ▲8.9pp | −17.5pp |
Operating margin | −16.3% | −16.3% | −34.8% | −12.3% | −17.5% | 28.3% | ▲18.5pp | −44.7pp |
Net margin22nd pct in Healthcare | −20.6% | −20.6% | −37.9% | −20.4% | −19.7% | 23.7% | ▲17.3pp | −44.2pp |
† FY25 = fiscal 2025, through 2025-09-30; the trailing year is not available.FY21 effective tax rate was 17% vs a −7% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was −52% vs a −7% norm for this window, likely a one-time item; see the filing.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-01-29 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Universe Pharmaceuticals' revenue last fiscal year?
Universe Pharmaceuticals reported revenue of $17.9B in fiscal 2025, down 22.4% from fiscal 2024.
What was Universe Pharmaceuticals' net income?
Universe Pharmaceuticals reported net income of −$3.7B in fiscal 2025, a net margin of −20.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

